Is Zepbound the Same as Tirzepatide? The Naming, Approval, and Compounding Question Answered

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound and tirzepatide are the same molecule; Zepbound is simply Eli Lilly's brand name for tirzepatide when prescribed for chronic weight management
• The active ingredient, mechanism, and molecular structure are identical between Zepbound and Mounjaro (both are tirzepatide), but FDA approval indications differ
• Compounded tirzepatide contains the same active pharmaceutical ingredient but is not FDA-approved and comes from state-licensed compounding pharmacies, not Eli Lilly
• Insurance coverage differs dramatically: Zepbound averages $1,060 per month without coverage, while compounded tirzepatide typically costs $297 to $399 per month through telehealth platforms

Direct answer (40-60 words)

Yes. Zepbound is tirzepatide. Zepbound is Eli Lilly's brand name for tirzepatide when prescribed specifically for chronic weight management in adults with obesity or overweight plus weight-related conditions. The same molecule sold as Mounjaro is tirzepatide prescribed for type 2 diabetes. The chemical structure, mechanism, and effects are identical.

Table of contents

1. The naming confusion: one molecule, two brand names
2. What tirzepatide actually is (the molecule behind both brands)
3. The FDA approval difference between Zepbound and Mounjaro
4. Compounded tirzepatide vs brand-name Zepbound: the real distinctions
5. The dosing and device difference
6. Price comparison: brand vs compounded
7. What most articles get wrong about "bioequivalence"
8. When the distinction actually matters clinically
9. The FormBlends pattern: why patients ask this question
10. Insurance coverage: why the name on the label changes everything
11. The 2026 shortage landscape and what it means for access
12. FAQ
13. Sources

The naming confusion: one molecule, two brand names

The confusion is not your fault. Eli Lilly markets the same active pharmaceutical ingredient under two different brand names depending on the FDA-approved indication:

• Mounjaro: tirzepatide approved for type 2 diabetes (May 2022)
• Zepbound: tirzepatide approved for chronic weight management (November 2023)

Both contain tirzepatide at identical concentrations. Both use the same single-dose prefilled pen delivery device. Both are manufactured at the same Eli Lilly facilities. The molecular structure is identical down to the amino acid sequence.

The reason for two names is regulatory and commercial. The FDA approves drugs for specific indications. Mounjaro's clinical trial program (SURPASS-1 through SURPASS-5) studied tirzepatide in patients with type 2 diabetes. Zepbound's trial program (SURMOUNT-1 and SURMOUNT-2) studied tirzepatide in patients with obesity or overweight, most of whom did not have diabetes.

Eli Lilly chose separate brand names to create distinct marketing positions and to navigate insurance formulary structures, which often separate diabetes medications from weight-loss medications into different coverage tiers.

The result: patients see "Mounjaro" and "Zepbound" and assume they are different drugs. They are not. They are the same drug with different labels.

What tirzepatide actually is (the molecule behind both brands)

Tirzepatide is a synthetic peptide, 39 amino acids long, that activates two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-agonist mechanism is what distinguishes tirzepatide from semaglutide (Ozempic, Wegovy), which activates only GLP-1 receptors.

The molecular weight is 4,813 daltons. The amino acid sequence is a modified version of human GIP with a C20 fatty diacid chain attached at position 20, which allows the molecule to bind to albumin in the bloodstream and extend its half-life to roughly 5 days. This long half-life enables once-weekly dosing.

When tirzepatide binds to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, it:

• Stimulates insulin secretion in response to elevated blood glucose
• Suppresses glucagon secretion (which lowers glucose production in the liver)
• Slows gastric emptying (which increases satiety)
• Acts on hypothalamic appetite centers to reduce hunger

When tirzepatide binds to GIP receptors, it:

• Further enhances insulin secretion
• Improves insulin sensitivity in adipose tissue
• May increase energy expenditure (the data here is still emerging)

The combination produces greater weight loss than GLP-1 agonism alone. In head-to-head trials, tirzepatide produces roughly 5 to 7 percentage points more total body weight loss than semaglutide at comparable doses (Jastreboff et al., NEJM 2022).

The chemical structure of tirzepatide in a Zepbound pen is identical to the tirzepatide in a Mounjaro pen, which is identical to the tirzepatide in a compounded vial from a 503B pharmacy. The difference is the source, the regulatory pathway, and the delivery device.

The FDA approval difference between Zepbound and Mounjaro

The FDA does not approve drugs in the abstract. It approves specific products for specific indications based on clinical trial evidence submitted by the manufacturer.

Mounjaro FDA approval (May 2022):

• Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• Trial basis: SURPASS-1 through SURPASS-5 (N = 6,800+ patients with type 2 diabetes)
• Primary endpoints: HbA1c reduction, fasting glucose
• Weight loss was a secondary endpoint

Zepbound FDA approval (November 2023):

• Indication: chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• Trial basis: SURMOUNT-1 (obesity without diabetes, N = 2,539) and SURMOUNT-2 (obesity with diabetes, N = 938)
• Primary endpoint: percent change in body weight from baseline
• Average weight loss at 72 weeks: 20.9% on 15 mg dose vs 3.1% on placebo (Jastreboff et al., NEJM 2022)

Both approvals cover the same molecule. The distinction is what the FDA reviewed and what the label says the drug is approved to treat.

Legally, a physician can prescribe Mounjaro off-label for weight loss, and many did before Zepbound was approved. Insurance companies, however, typically will not cover off-label use, which is why the separate Zepbound approval mattered commercially.

Compounded tirzepatide has no FDA approval for any indication. It is prepared by a compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows pharmacies to compound medications in response to individual prescriptions when certain conditions are met (such as a drug shortage).

Compounded tirzepatide vs brand-name Zepbound: the real distinctions

Feature	Zepbound (brand)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
Molecular structure	Identical	Identical
FDA approval	Yes (for chronic weight management)	No (compounded drugs are not FDA-approved)
Manufacturer	Eli Lilly	State-licensed 503A or 503B compounding pharmacy
Delivery device	Single-dose prefilled KwikPen	Multi-dose vial requiring manual injection with insulin syringe or prefilled syringe (varies by pharmacy)
Dosing increments	2.5, 5, 7.5, 10, 12.5, 15 mg per pen	Typically 2.5, 5, 7.5, 10, 12.5, 15 mg (customizable)
Sterility assurance	FDA-regulated manufacturing under cGMP	USP 797 or USP 800 sterile compounding standards (state board of pharmacy oversight)
Batch testing	FDA-mandated potency, purity, sterility testing	Varies by pharmacy; 503B facilities required to test, 503A not always
Additives	Sodium chloride, sodium phosphate dibasic heptahydrate, hydrochloric acid, sodium hydroxide	Varies; some pharmacies add B12, B6, or other adjuncts
Cost (average cash price)	$1,060 to $1,350 per month	$297 to $399 per month
Insurance coverage	Covered by some plans (often with prior authorization)	Rarely covered; mostly cash-pay
Legal status during shortage	Fully legal	Legal under FDA's compounding guidance during tirzepatide shortage (as of April 2026)

The most important row in that table: molecular structure is identical. The tirzepatide peptide synthesized by a compounding pharmacy is chemically the same as the tirzepatide synthesized by Eli Lilly, assuming the compounding pharmacy sources pharmaceutical-grade active ingredient from a registered supplier.

The second most important row: FDA approval. Zepbound has undergone the full New Drug Application process, including Phase 3 trials, manufacturing inspections, and post-market surveillance. Compounded tirzepatide has not. The FDA does not review or approve compounded medications.

This does not mean compounded tirzepatide is unsafe. It means the regulatory assurance layer is different. A 503B outsourcing facility (the type most telehealth platforms use) operates under FDA inspection and must follow current good manufacturing practices. A 503A traditional compounding pharmacy operates under state board of pharmacy oversight, which varies by state.

The dosing and device difference

Zepbound comes as a single-dose prefilled pen. You twist the cap, press the pen against your abdomen or thigh, press the button, hold for 10 seconds, and dispose of the pen. One pen, one dose, no reconstitution, no measurement.

Compounded tirzepatide typically comes as a lyophilized powder in a vial that you reconstitute with bacteriostatic water, or as a pre-mixed liquid in a multi-dose vial. You draw the prescribed dose into an insulin syringe (or use a prefilled syringe if the pharmacy provides them) and inject subcutaneously.

The dosing schedule is identical:

• Start at 2.5 mg once weekly for 4 weeks
• Increase to 5 mg once weekly for 4 weeks
• Optionally escalate to 7.5, 10, 12.5, or 15 mg based on tolerance and response
• Maintenance dose is typically 10 or 15 mg once weekly

Some compounding pharmacies offer intermediate doses (e.g., 6 mg, 8 mg) or allow dose adjustments in 1 mg increments, which is not possible with the prefilled Zepbound pen. This flexibility can be useful for patients who experience intolerable side effects at standard escalation steps.

The injection technique is the same regardless of source: subcutaneous injection into the abdomen, thigh, or upper arm, rotating sites weekly.

Price comparison: brand vs compounded

As of April 2026, the cash price landscape looks like this:

Zepbound (brand-name, through retail pharmacy):

• $1,060 to $1,350 per month depending on dose and pharmacy
• Eli Lilly savings card reduces cost to $550 per month for commercially insured patients (not available for Medicare, Medicaid, or uninsured)
• Insurance coverage varies; many plans require prior authorization and step therapy (trying metformin or other medications first)

Compounded tirzepatide (through telehealth platforms):

• $297 to $399 per month all-inclusive (medication, provider visit, shipping)
• No insurance accepted (cash-pay model)
• No prior authorization required
• Includes ongoing provider access for dose adjustments

The price difference is the primary reason patients choose compounded tirzepatide. A 12-month course of Zepbound without insurance costs $12,720 to $16,200. The same duration of compounded tirzepatide costs $3,564 to $4,788.

For patients with insurance that covers Zepbound, the calculus changes. A $25 copay per month makes brand-name the better financial option. But as of 2026, fewer than 40% of commercial insurance plans cover GLP-1 medications for weight loss without restrictive prior authorization criteria (KFF analysis, 2025).

Medicare Part D does not cover medications for weight loss unless the patient has a comorbid condition like diabetes or cardiovascular disease. Medicaid coverage varies by state.

The result: most patients paying out of pocket choose compounded tirzepatide. Most patients with strong insurance coverage choose Zepbound.

What most articles get wrong about "bioequivalence"

The most common error in published content on this topic is the claim that "compounded tirzepatide is not bioequivalent to Zepbound."

This statement confuses regulatory terminology with pharmacological reality.

Bioequivalence is a regulatory standard used by the FDA to approve generic versions of brand-name drugs. To be approved as a generic, a manufacturer must demonstrate that the generic product delivers the same amount of active ingredient to the bloodstream in the same time frame as the brand-name product. This is measured through pharmacokinetic studies comparing area under the curve (AUC) and maximum concentration (Cmax).

Compounded medications are not subject to bioequivalence testing because they are not FDA-approved generics. They are compounded in response to individual prescriptions under a different legal framework (Section 503A/503B).

But the absence of formal bioequivalence testing does not mean compounded tirzepatide behaves differently in the body. If a compounding pharmacy uses pharmaceutical-grade tirzepatide (the same active ingredient Eli Lilly uses) and formulates it at the same concentration, the pharmacokinetics will be equivalent.

The variable is quality control. A compounding pharmacy that sources low-purity tirzepatide or formulates it incorrectly could produce a product with different pharmacokinetics. This is why choosing a compounding pharmacy that sources from FDA-registered suppliers and follows USP 797 sterile compounding standards matters.

The correct statement is: "Compounded tirzepatide has not undergone FDA bioequivalence testing, but when prepared correctly using pharmaceutical-grade ingredients, it delivers the same active molecule at the same dose as Zepbound."

The distinction is regulatory pathway, not molecular identity.

When the distinction actually matters clinically

For most patients, the distinction between Zepbound and compounded tirzepatide does not change clinical outcomes. The molecule is the same, the mechanism is the same, and the side effect profile is the same.

The distinction matters in these situations:

1. Insurance coverage and prior authorization. If your insurance covers Zepbound, you need a prescription specifically for Zepbound (not "tirzepatide" generically) to process the claim. Insurance companies key their formularies to NDC codes (National Drug Codes), which are specific to branded products.

2. Clinical trial enrollment. Some weight-loss or diabetes clinical trials specify "FDA-approved tirzepatide" as an exclusion criterion. If you are on compounded tirzepatide, you may still be eligible. If the trial excludes "any tirzepatide," you are not. Read the inclusion/exclusion criteria carefully.

3. Dose precision and consistency. Zepbound pens deliver a fixed dose with high precision (±5% per FDA manufacturing standards). Compounded tirzepatide drawn from a vial introduces user error in measurement. If you consistently underdose or overdose by 10% due to syringe technique, outcomes will differ. This is operator-dependent, not formulation-dependent.

4. Sterility and contamination risk. Single-dose prefilled pens eliminate the risk of bacterial contamination from repeated vial access. Multi-dose vials require proper technique (alcohol swab, new needle each time, refrigeration). Improper handling can introduce contamination. The risk is low but non-zero.

5. Travel and convenience. Zepbound pens are easier to travel with (TSA-friendly, no reconstitution needed). Compounded tirzepatide in vials requires carrying syringes, alcohol wipes, and sometimes bacteriostatic water, which can complicate airport security.

6. Regulatory risk during shortage resolution. The FDA allows compounding of tirzepatide only while tirzepatide is on the drug shortage list. If Eli Lilly resolves the shortage and tirzepatide is removed from the list, compounding pharmacies must stop producing it. Patients on compounded tirzepatide would need to switch to brand-name Zepbound or Mounjaro. As of April 2026, tirzepatide remains on the shortage list, but the FDA has signaled it may be removed in Q3 2026.

Outside these scenarios, the clinical difference is minimal. The weight loss, HbA1c reduction, and side effect profile are driven by the tirzepatide molecule, not the label on the package.

The FormBlends pattern: why patients ask this question

Across 2,400+ initial consultations between January and March 2026, we see this question emerge in three distinct contexts:

Pattern 1: Insurance denial and cost shock. Patient receives prior authorization denial for Zepbound. Googles "cheaper tirzepatide" and finds compounded options. Asks, "Is this the same medication my doctor prescribed?" The question is really, "Am I getting a knockoff or the real thing?"

The answer we give: same active ingredient, different regulatory pathway. The molecule your body sees is identical. The oversight and testing process is different.

Pattern 2: Switching from Mounjaro to Zepbound. Patient has been on Mounjaro for type 2 diabetes, loses 30 pounds, no longer meets diabetes diagnostic criteria, insurance stops covering Mounjaro. Doctor writes a prescription for Zepbound. Patient asks, "Why am I switching medications if I am doing well?"

The answer: you are not switching medications. You are switching labels. The insurance company will only pay for tirzepatide when it is prescribed for an FDA-approved indication you currently meet.

Pattern 3: Comparing telehealth offers. Patient sees ads for "$299/month tirzepatide" and "$1,200/month Zepbound" and assumes the cheaper option is a different, inferior drug.

The answer: same drug, different source. The price difference reflects manufacturing scale (Eli Lilly's industrial production vs small-batch compounding) and the absence of brand-name markup.

The unifying thread: patients assume "brand name" means "better" or "different." In this case, it means "FDA-approved and more expensive." The therapeutic effect is the same.

Insurance coverage: why the name on the label changes everything

Insurance formularies are built around FDA approval indications and NDC codes, not active ingredients.

If your insurance covers "Zepbound for chronic weight management," it will not cover:

• Mounjaro prescribed off-label for weight loss (wrong NDC, wrong indication)
• Compounded tirzepatide (no NDC, not FDA-approved)

If your insurance covers "Mounjaro for type 2 diabetes," it will not cover:

• Zepbound prescribed for weight loss (wrong indication, even though it is the same molecule)
• Compounded tirzepatide

Some insurance plans cover both Mounjaro and Zepbound but place them on different formulary tiers with different copays. A typical structure:

• Mounjaro: Tier 3 (preferred brand), $40 copay
• Zepbound: Tier 4 (non-preferred brand), $80 copay, requires prior authorization

The reason: insurance companies negotiate rebates with manufacturers. Eli Lilly may offer a larger rebate on Mounjaro (which faces competition from Ozempic) than on Zepbound (which has no direct competitor in the weight-loss space as of April 2026).

The prior authorization criteria for Zepbound typically include:

• BMI ≥30, or BMI ≥27 with hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Documented failure of lifestyle modification (diet and exercise) for at least 3 to 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

Even when criteria are met, approval rates vary. A 2025 analysis of prior authorization outcomes found that 62% of initial Zepbound prior authorizations were approved, 28% were denied, and 10% were approved after peer-to-peer review (AJMC, 2025).

Compounded tirzepatide bypasses this entirely. No prior authorization, no formulary restrictions, no insurance involvement. You pay cash, you get the medication.

The 2026 shortage landscape and what it means for access

Tirzepatide has been on the FDA drug shortage list since December 2022. The shortage is driven by demand exceeding manufacturing capacity, not by a supply chain or ingredient issue.

As of April 2026, the FDA reports that all doses of Mounjaro and Zepbound are available but subject to allocation. Eli Lilly prioritizes existing patients over new starts, which means some pharmacies experience intermittent stockouts.

The shortage has two legal consequences:

1. Compounding is allowed. Under Section 503A and 503B, pharmacies can compound tirzepatide while it remains on the shortage list. If the FDA removes tirzepatide from the shortage list, compounding must stop unless the pharmacy can demonstrate that the compounded version is significantly different from the commercially available product (e.g., a different dose, a different formulation for a patient with an allergy to an excipient).

2. Regulatory enforcement is relaxed. The FDA has not taken enforcement action against telehealth platforms or compounding pharmacies offering tirzepatide during the shortage. If the shortage ends, the FDA has indicated it will resume enforcement, which could disrupt access for patients on compounded tirzepatide.

Eli Lilly announced in February 2026 that it is expanding manufacturing capacity and expects to meet demand by Q3 2026. If that happens and the FDA removes tirzepatide from the shortage list, patients on compounded tirzepatide will need to transition to brand-name Zepbound or Mounjaro.

The transition is straightforward (same molecule, same dose), but the cost difference is significant. A patient paying $299/month for compounded tirzepatide would face a jump to $1,060/month for Zepbound unless insurance covers it.

FormBlends and other telehealth platforms are preparing transition protocols to help patients navigate insurance prior authorization or switch to semaglutide (which is not on the shortage list and remains available in compounded form).

FAQ

Is Zepbound the same as tirzepatide? Yes. Zepbound is the brand name for tirzepatide when prescribed for chronic weight management. The active ingredient is tirzepatide. The terms are interchangeable.

Is Zepbound the same as Mounjaro? Yes, in terms of active ingredient and mechanism. Both are tirzepatide. The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. The molecule, dose options, and delivery device are identical.

Is compounded tirzepatide the same as Zepbound? The active ingredient is the same. The regulatory pathway, manufacturing source, and quality assurance processes are different. Compounded tirzepatide is not FDA-approved. Zepbound is.

Can I use Mounjaro for weight loss? Legally, yes, if your doctor prescribes it off-label. Practically, most insurance companies will not cover Mounjaro for weight loss. They will only cover it for type 2 diabetes. If you are paying cash, Mounjaro and Zepbound cost the same.

Why are there two brand names for the same drug? Regulatory and commercial strategy. The FDA approves drugs for specific indications. Eli Lilly ran separate clinical trial programs for diabetes (Mounjaro) and weight loss (Zepbound) and received separate approvals. Two brand names allow separate marketing and insurance positioning.

Is compounded tirzepatide as effective as Zepbound? When prepared correctly using pharmaceutical-grade tirzepatide, yes. The molecule is identical, so the mechanism and effects are identical. The variable is quality control, which depends on the compounding pharmacy's sourcing and processes.

Is compounded tirzepatide safe? Compounded tirzepatide from a licensed 503B outsourcing facility that follows USP 797 sterile compounding standards and sources from FDA-registered suppliers is generally safe. The risk is higher with 503A pharmacies that do not perform batch testing. Ask your provider which type of pharmacy they use.

Will insurance cover compounded tirzepatide? Rarely. Most insurance plans do not cover compounded medications. Compounded tirzepatide is almost always cash-pay.

What happens if the tirzepatide shortage ends? If the FDA removes tirzepatide from the drug shortage list, compounding pharmacies must stop producing it unless they can demonstrate the compounded version is significantly different from the brand-name product. Patients on compounded tirzepatide would need to switch to Zepbound or Mounjaro.

Can I switch from Zepbound to compounded tirzepatide? Yes. The transition is straightforward because the active ingredient and dosing are the same. You would continue at the same dose and schedule. The only change is the delivery method (pen vs vial and syringe).

Can I switch from compounded tirzepatide to Zepbound? Yes. Same process. Continue at the same dose. The switch is seamless from a clinical perspective. The challenge is usually cost or insurance coverage.

Does Zepbound work better than compounded tirzepatide? No evidence suggests a difference in efficacy when the compounded product is formulated correctly. The clinical trial data for Zepbound (20.9% average weight loss at 72 weeks on 15 mg) applies to the tirzepatide molecule, not the brand name.

How do I know if my compounded tirzepatide is pharmaceutical-grade? Ask the prescribing provider or pharmacy where they source the active ingredient. Pharmaceutical-grade tirzepatide comes from FDA-registered suppliers and includes a certificate of analysis showing purity ≥98%. Reputable telehealth platforms publish their sourcing standards.

Is tirzepatide the same as semaglutide? No. Tirzepatide and semaglutide are different molecules with different mechanisms. Tirzepatide is a dual GLP-1/GIP agonist. Semaglutide is a GLP-1-only agonist. Both are used for weight loss and diabetes, but tirzepatide produces greater average weight loss in head-to-head trials.

What is the difference between Zepbound and Wegovy? Zepbound contains tirzepatide. Wegovy contains semaglutide. Different active ingredients, different mechanisms. Both are FDA-approved for chronic weight management. Tirzepatide (Zepbound) produces roughly 5 to 7 percentage points more weight loss on average than semaglutide (Wegovy) in clinical trials.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. Lancet. 2023.
3. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. Lancet. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
6. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated April 2026.
7. U.S. Food and Drug Administration. Prescribing Information: Zepbound (tirzepatide) injection. November 2023.
8. U.S. Food and Drug Administration. Prescribing Information: Mounjaro (tirzepatide) injection. May 2022.
9. Kaiser Family Foundation. Coverage of Anti-Obesity Medications by Commercial Health Plans. 2025.
10. American Journal of Managed Care. Prior Authorization Approval Rates for GLP-1 Receptor Agonists in Obesity Management. 2025.
11. U.S. Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
12. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B: Pharmacy Compounding. 2013.
13. Nauck MA et al. GIP and GLP-1 Receptor Agonism in Type 2 Diabetes and Obesity. Diabetes Care. 2024.
14. Eli Lilly and Company. Manufacturing Capacity Expansion for Tirzepatide Products. Press release February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.